Avalo Therapeutics 2025 Q3 Earnings Deepening Losses Amid Clinical Trial Progress

, . The company attributed the loss to R&D and G&A expenses, . Despite financial challenges, Avalo highlighted progress in its Phase 2 LOTUS trial for AVTX-009, .

Revenue

, , , 2023.

Earnings/Net Income

, , . The EPS and net loss underscore ongoing financial headwinds despite clinical progress.

Price Action

, .

Post-Earnings Price Action Review

The strategy of buying AVTX shares after its Q3 earnings release and holding for 30 days underperformed, . This poor performance likely reflects persistent market skepticism about Avalo’s financial health and uncertain clinical outcomes, despite its pipeline advancements.

CEO Commentary

Dr. , . , including new appointments in business development and HR, to support long-term goals. .

Guidance

. , .

Additional News

, , HR). , .